Key Highlights
- CG Oncology (NASDAQ:CGON) closed up 13.95% on Monday, November 16, 2026, one of the best performing mid-cap stocks on a weak day for the market.
- Its Phase 3 PIVOT-006 trial showed that cretostimogene reduced the risk of cancer recurrence by 68% compared with surveillance alone, with a hazard ratio of 0.32.
- The trial enrolled 367 patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer, and reported no grade 3 or higher treatment-related side effects.
- The company plans a second Biologics license application for this population in the second quarter of 2027.
What the Trial Showed
PIVOT-006 tested cretostimogene, a gene therapy based on a modified virus that is delivered directly into the bladder, in patients whose tumors had been fully removed by surgery but who remain at meaningful risk of the cancer returning. The trial randomized 367 patients at about 90 sites in the United States and Canada to treatment or to surveillance, which is a common approach for intermediate-risk disease today. Cretostimogene reduced the risk of recurrence by 68%, with a hazard ratio of 0.32, a 95% confidence interval of 0.23 to 0.45 and a p-value below 0.0001, a highly statistically significant result. Median follow-up was 17 months as of October 26, 2026. Safety was a key part of the story. There were no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations, which matters for a population of patients who are not facing an immediately life-threatening cancer and may be treated for long periods. The company described the improvement in recurrence-free survival as unprecedented for this patient group, and full results will be presented as a late-breaking abstract at a major urology meeting on December 2, 2026. The size of the effect and the consistency of the safety data are what set this readout apart, since earlier treatments for this population have often traded efficacy for side effects that limit how long patients stay on therapy.
Why It Matters Commercially
Non-muscle invasive bladder cancer is one of the most common cancers in the United States, and many patients face repeated recurrences and procedures over many years. Intermediate-risk patients currently have limited proven Options after surgery, so a well-tolerated therapy that sharply cuts recurrence could address a large market. CG Oncology is already pursuing approval in a different, higher risk group: patients whose disease no longer responds to standard BCG therapy, supported by its BOND-003 trial. The drug holds Fast Track and Breakthrough Therapy designations in that setting, and the company plans to broaden its initial application to include high-grade papillary-only disease, with completion before the end of March 2027. The PIVOT-006 data would support a second application in intermediate-risk and high-grade Ta disease in the second quarter of 2027. Manufacturing for both filings is complete, which reduces a common source of delay in biotech launches. The stock briefly traded more than 30% higher before the open, then settled for a 13.95% gain as the broader market sold off. For a company with a Market Value of several billion dollars, the opening of a second, larger patient population materially changes the potential Revenue base if both applications are approved.
What Investors Weigh Now
The next milestones are the December 2 presentation, which will provide detail on subgroups and durability, and the completion of the first application by the end of March 2027. Investors will also weigh competition from other bladder cancer therapies, the price the company can command and the cost of building a commercial team. Biotech stocks remain sensitive to interest rates and market sentiment, which can affect valuations even after strong data. Funding is a further consideration, though positive data typically make it easier for companies to raise Capital on favorable terms ahead of a launch.
Where Things Stand
CG Oncology rose 13.95% after PIVOT-006 showed a 68% reduction in recurrence risk with a clean safety profile. The December 2 presentation and regulatory filings in early and mid 2027 are the next catalysts.






Please wait processing your request...